tirzepatide cvot results Systolic blood pressure reduction with in patients with type 2 diabetes: insights from SURPASS clinical program | Cardiovascular Diabetology SURPASS-CVOT Published: Large Trial Confirms

References & Sources SURPASS-2 Trial (N Engl J Med) SURMOUNT-1 Trial (N Engl J Med) SELECT Trial Semaglutide CV Outcomes (N Engl J Med) SUMMIT Trial Tirzepatide HFpEF (N Engl J Med) Eli Lilly SURPASS-2 Results (Press Release) Eli Lilly SURMOUNT-1 Results (Press Release) ADA SURPASS Data Presentation SUMMIT Trial ACC Summary SELECT Trial ACC Summary Disclaimer: This information is intended for general knowledge and informational purposes only and does not constitute medical advice

Outlook (Prognosis) Proper treatment will ease symptoms most of the time

The contribution of psychiatric AEs in GLP-1 RAs is not prominent compared with the background frequency of the SOC level, but with the dramatic increase in the number of GLP-1 RAs used, psychiatric AEs remain a notable proportion of the overall AEs associated with GLP-1 RAs ( Table 1 )

Retrieved from Liang, W., Zhao, Y., Cai, B., et al